MDT-AP-0823
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 32
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.919970332
- umap2_2d
- 4.58138253
- umap1_3d
- 3.187906051
- umap2_3d
- -2.292161485
- umap3_3d
- -3.119626615
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.290
- PANCREAS_BETA_CELLS+0.260
- APICAL_JUNCTION+0.230
- CHOLESTEROL_HOMEOSTASIS+0.220
- MYOGENESIS+0.210
- GLYCOLYSIS+0.200
- HEDGEHOG_SIGNALING+0.190
- UV_RESPONSE_UP+0.190
- PI3K_AKT_MTOR_SIGNALING+0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
Top 10 suppressed
- E2F_TARGETS-0.410
- MYC_TARGETS_V1-0.410
- G2M_CHECKPOINT-0.350
- ALLOGRAFT_REJECTION-0.340
- INTERFERON_ALPHA_RESPONSE-0.230
- ANDROGEN_RESPONSE-0.190
- TGF_BETA_SIGNALING-0.170
- IL6_JAK_STAT3_SIGNALING-0.160
- UV_RESPONSE_DN-0.160
- INTERFERON_GAMMA_RESPONSE-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613710 | — | F | 0.757 |
| 2 | TCGA-AC-A3EH-01A-22R-A22K-07 | — | B | 0.756 |
| 3 | SRR8518440 | — | C | 0.738 |
| 4 | 20050118.TNBC | — | F | 0.719 |
| 5 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.718 |
| 6 | MNG965 | — | — | 0.708 |
| 7 | SRR8613707 | — | C | 0.701 |
| 8 | SRR1797236 | — | cohortSC | 0.700 |
| 9 | 3698f158-b7ab-4ad0-9064-ee1269a17821 | — | — | 0.696 |
| 10 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.695 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |